Diagnostics company Immunovia (Nasdaq Stockholm: IMMNOV) reported on Monday that it is continuing to commercialise its IMMray PanCan-d test in the US with the appointment of a new national sales director by its US subsidiary, Immunovia Inc.
The company's IMMray PanCan-d test is the world's first blood test dedicated to the early detection of pancreatic cancer.
Commercialization of IMMray PanCan-d started in August 2021 in the US. The test is offered as a laboratory developed test (LDT) exclusively through Immunovia Inc.
Immunovia added that Jon Hager starts in his position of national sales director on 5 December 2022.
Hager worked at Myriad Genetics where he was a core member of the team that launched hereditary cancer testing to gynecologists.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients